New Site Launching Soon

EnteroBiotix is harnessing the human microbiome to develop novel medicinal products that restore health and prevent disease. The Company’s first focus is to unlock the full therapeutic potential of faecal microbiota transplantation (FMT) through a field-leading GMP-compliant minimally manipulated microbiome platform and an ex-vivo microbiome engineering platform. EnteroBiotix has deep operational experience and capabilities, including fully integrated ISO-accredited microbial collection and GMP-compliant processing capabilities under a ‘specials’ license from the Medicines and Healthcare Products Regulatory Agency (MHRA). Since its formation in March 2017, EnteroBiotix has raised over £2m in funding and has a strategic collaboration with the Academic Health Science Partnership and National Health Service in Tayside, Scotland.

For more information, please contact

Cookie Policy

This website uses cookies to ensure you get the best experience on our website.

You can view our privacy policy here